For the first time, scientists have measured the shape of an electron in solids, opening the door to advances in quantum ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

There are 203 funds or institutions reporting positions in IGM Biosciences. This is an decrease of 5 owner(s) or 2.40% in the last quarter. Average portfolio weight of all funds dedicated to IGMS ...

Stock tumbles to continue slide that started after the company switched to autoimmunity from oncology late last year IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after ...

(RTTNews) - Biotechnology company IGM Biosciences, Inc. (IGMS), Thursday announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

Analyst Tom Mackinnon of BMO Capital maintained a Hold rating on IGM Financial (IGIFF – Research Report), retaining the price target of ...